Design of new drug molecules to be used in reversing multidrug resistance in cancer cells.

abstract：:Targets for cancer therapy are conventionally selected by identification of molecules acting downstream of established tumour suppressors and oncoproteins, such as p53, c-Myc and Ras. However, the forward genetics approach provides an alternative, conceptually distinct, strategy for identifying target molecules de nov...

journal_title：Current cancer drug targets

authors： Mourtada-Maarabouni M,Watson D,Munir M,Farzaneh F,Williams GT

更新日期：2013-01-01 00:00:00

abstract：:Cell-penetrating peptides (CPPs) have been previously shown to be powerful transport vector tools for the delivery of a large variety of cargoes through the cell membrane, as well as other physiological membranes. And since they're relatively cell-, receptor- and energy-independent, CPPs have unique advantages in faci...

journal_title：Current cancer drug targets

authors： Wang W,Abbad S,Zhang Z,Wang S,Zhou J,Lv H

更新日期：2015-01-01 00:00:00

abstract：:The histone deacetylase inhibitors are a new class of cytostatic agents that inhibit the proliferation of tumor cells in culture and in vivo by inducing cell cycle arrest, differentiation and/or apoptosis. Histone acetylation and deacetylation play important roles in the modulation of chromatin topology and the regula...

journal_title：Current cancer drug targets

authors： Vigushin DM,Coombes RC

更新日期：2004-03-01 00:00:00

abstract：:Autophagy is an intracellular lysosomal/vacuolar degradation system, in which the inner cytoplasmic cell membrane is degraded by the lysosomal hydrolases, followed by the resulting products released back into the cytosol. It is involved in many physiological processes which are crucial for cell growth and survival. Ho...

journal_title：Current cancer drug targets

authors： Zhou X,Yue GG,Tsui SK,Pu J,Fung KP,Lau CB

更新日期：2018-01-01 00:00:00

abstract：:One of the crucial reasons of breast cancer therapy failure is an impairment of mechanisms responsible for metabolism and cellular homeostasis, which makes it difficult to foresee the response to the treatment. Targeted therapy in breast cancer is dictated by the expression of specific molecules such as growth factor ...

journal_title：Current cancer drug targets

authors： Lisiak N,Toton E,Rybczynska M

更新日期：2018-01-01 00:00:00

abstract：:The epidermal growth factor (EGFR) and its receptor were discovered nearly 40 years ago. Over the past decade interruption of this pathway has been exploited in the treatment of various solid tumors. Antibodies that interfere with ligand binding to and dimerization of the EGFR (and small molecules that inhibit the EGF...

journal_title：Current cancer drug targets

authors： Astsaturov I,Cohen RB,Harari P

更新日期：2007-11-01 00:00:00

abstract：:Bisphosphonates are the standard of care for preventing skeletal morbidity and treating hypercalcemia of malignancy in patients with bone metastases. Zoledronic acid (intravenous; 4 mg monthly) is approved to prevent skeletal-related events (SREs) in patients with bone metastases from several tumor types, and can impr...

journal_title：Current cancer drug targets

authors： Gnant M

更新日期：2009-11-01 00:00:00

abstract：:Angiogenesis is crucial for tumor development and progression, and antiangiogenetic therapy represents a promising approach for cancer treatment. Thus, the in-depth understanding of the molecular mechanism(s) regulating angiogenesis, together with the characterization of molecules expressed by endothelial cells and in...

journal_title：Current cancer drug targets

authors： Fonsatti E,Sigalotti L,Arslan P,Altomonte M,Maio M

更新日期：2003-12-01 00:00:00

abstract：:The resistance of tumors to a number of structurally and functionally unrelated chemotherapeutic drugs has been a major obstacle for successful cancer chemotherapy. An important mechanism leading to multidrug resistance (MDR) is the overexpression of the 170 kDa P-glycoprotein (P-gp), which is a member of the ATP-bind...

journal_title：Current cancer drug targets

authors： Santos SA,Paulo A

更新日期：2013-10-01 00:00:00

abstract：:Exosomes are small vesicles that are secreted by various types of cells, known to mediate signal transduction between cells. During recent years, novel carriers for the delivery of targeted drugs, chemotherapy drugs and RNAs are under development, which is believed to be beneficial for patients. Considering issues of ...

journal_title：Current cancer drug targets

authors： Wang X,Zhang H,Yang H,Bai M,Ning T,Li S,Li J,Deng T,Ying G,Ba Y

更新日期：2018-01-01 00:00:00

abstract：:Haem oxygenase-1 (HO-1) catalyses the rate-limiting step in haem degradation. All three metabolites resulting from haem degradation (carbon monoxide (CO), biliverdin and free iron) have anti-inflammatory and anti-apoptotic properties. HO-1 is a stress-inducible enzyme found extensively expressed in a vast variety of b...

journal_title：Current cancer drug targets

authors： Hjortsø MD,Andersen MH

更新日期：2014-01-01 00:00:00

abstract：:Recent publications on the molecular characterization of malignant glioma have had profound impact on the appreciation of tumoral heterogeneity within and between patients. Both these phenomena are implicated in the variability in clinical outcome between patients, as well as the inevitable recurrence of these tumors ...

journal_title：Current cancer drug targets

authors： Balvers RK,Dirven CM,Leenstra S,Lamfers ML

更新日期：2017-01-01 00:00:00

abstract：:Prostate cancer is the most frequently diagnosed tumor in industrialized countries. Endocrine therapy, which is based on interference with androgen signaling is only palliative. Drugs used in prostate cancer therapy are luteinizing hormone releasing hormone (LHRH) agonists and antiandrogens. Application of LHRH agonis...

journal_title：Current cancer drug targets

authors： Culig Z,Bartsch G,Hobisch A

更新日期：2004-08-01 00:00:00

abstract：:The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) is an analogue of cytidine. Besides its antiviral effect, its potential use in the treatment of cancer has become an important area of research. CPEC is activated by intracellular phosphorylation ultimately forming its metabolite CPEC-TP. CPEC-TP is a non c...

journal_title：Current cancer drug targets

authors： Schimmel KJ,Gelderblom H,Guchelaar HJ

更新日期：2007-08-01 00:00:00

abstract：:FOXO proteins are evolutionarily conserved transcription factors implicated in several fundamental cellular processes, functioning as end-point for transcriptional programs involved in apoptosis, stress response and longevity. Abrogation of FOXO function is very frequent in human cancer, therefore the mechanisms of re...

journal_title：Current cancer drug targets

authors： Zanella F,Link W,Carnero A

更新日期：2010-03-01 00:00:00

abstract：BACKGROUND:Oncolytic viruses (OVs), which preferentially infect cancer cells and induce host anti-tumor immune responses, have emerged as an effective melanoma therapy. Tanapoxvirus (TANV), which possesses a large genome and causes mild self-limiting disease in humans, is potentially an ideal OV candidate. Interleukin-...

journal_title：Current cancer drug targets

authors： Zhang T,Kordish DH,Suryawanshi YR,Eversole RR,Kohler S,Mackenzie CD,Essani K

更新日期：2018-01-01 00:00:00

abstract：:Cisplatin is one of the most commonly used drugs in the treatment of gastric cancer. However, drug resistance is a major obstacle for effective treatment and originates in multiple mechanisms such as enhanced DNA repair and anti-apoptosis. Our previous results demonstrated that XRCC1 was a key regulator of cisplatin i...

journal_title：Current cancer drug targets

authors： Ni P,Xu W,Zhang Y,Chen Q,Li A,Wang S,Xu S,Zhou J

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Epidermal growth factor receptor (EGFR) is a well-recognised drug target exploited for treating non-small cell lung cancer (NSCLC). Gefitinib and erlotinib are first generation clinically employed inhibitors used against EGFR activating mutants. However, during course of treatment these inhibitors become ine...

journal_title：Current cancer drug targets

authors： Agarwal SM,Pal D,Gupta M,Saini R

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:CYP1B1 is recognized as a valuable target for chemotherapy. It catalyzes the bioactivation of naphthoquinone oximes within certain cancer cell lines. However, the expression level of CYP1B1 in melanoma and the functional role regulating the activity of DMAKO-20 as a representative naphthoquinone oxime agains...

journal_title：Current cancer drug targets

authors： Cui J,Zhou X,Huang J,Cui J,Chen J

更新日期：2020-11-15 00:00:00

abstract：:It has been estimated that greater than 35% of all human genes undergo alternative splicing. The process of alternative splicing is highly regulated and disruption of a splicing pattern can produce splice variants that have different functions. Certain splice variants that are associated with induction of cell death, ...

journal_title：Current cancer drug targets

authors： Mercatante DR,Sazani P,Kole R

更新日期：2001-11-01 00:00:00

abstract：:Cancer is a disease in which cellular growth regulatory networks are disrupted. Lesions in well-characterized oncogenes and tumor suppressors often contribute to the dysregulation, but recent work has also uncovered the fundamental importance of enzymes that modulate the acetylation status of chromatin to the initiati...

journal_title：Current cancer drug targets

authors： Chen JS,Faller DV,Spanjaard RA

更新日期：2003-06-01 00:00:00

abstract：:The integrin family of cell surface receptors integrates cell-extracellular matrix interactions with the cell cytoskeleton and signalling across the cell membrane, resulting in an important role in cell adhesion, mobility and migration, proliferation, and survival. Changes in the number and identity of integrin recept...

journal_title：Current cancer drug targets

authors： Sheldrake HM,Patterson LH

更新日期：2009-06-01 00:00:00

abstract：:The urokinase plasminogen activator (uPA) system (uPAS) consists of the uPA, its cognate receptor (uPAR) and two specific inhibitors, the plasminogen activator inhibitor 1 (PAI-1) and 2 (PAI-2). The uPA converts the proenzyme plasminogen in the serine protease plasmin, involved in a number of physiopathological proces...

journal_title：Current cancer drug targets

authors： Ulisse S,Baldini E,Sorrenti S,D'Armiento M

更新日期：2009-02-01 00:00:00

abstract：:One of the older and most validated cancer treatments is endocrine therapy. Some tumors are dependent on hormone stimulation for growth, and therefore therapeutic interventions aiming to deprive the cells of the hormone are feasible and have been successful. Tumor growth also depends in some cases on growth factors, s...

journal_title：Current cancer drug targets

authors： González G,Lage A

更新日期：2007-05-01 00:00:00

abstract：:Gardenia, the fruit of Gardenia jasminoides Ellis, has been widely used to treat liver and gall bladder disorders in Chinese medicine. It has been shown recently that geniposide, the main ingredient of Gardenia Fructus, exhibits the anti-tumor effect. In this review, we discuss the anti-tumor effect and possible mecha...

journal_title：Current cancer drug targets

authors： Peng CH,Huang CN,Wang CJ

更新日期：2005-06-01 00:00:00

abstract：:Amplification of the HER-2 gene occurs in approximately 25% of breast cancers, causing up-regulation of key signaling pathways which control cell growth and survival. In breast cancer patients, HER-2 overexpression correlates with an aggressive phenotype and poor prognosis. HER-2, therefore, has become the focus of ma...

journal_title：Current cancer drug targets

authors： Browne BC,O'Brien N,Duffy MJ,Crown J,O'Donovan N

更新日期：2009-05-01 00:00:00

abstract：:The ubiquitin system controls protein stability and function. F-box proteins form SCF (SKP1-Cullin1-F-box protein)-type ubiquitin (E3) ligases to selectively target their substrates for degradation via the ubiquitin-proteasome pathway. Here, we review F-box proteins associated with cancer development. S-phase kinase-a...

journal_title：Current cancer drug targets

authors： Kitagawa K,Kitagawa M

更新日期：2016-01-01 00:00:00

abstract：:Several subtypes of T cells are located in a tumor environment, each of which supplies their energy using different metabolic mechanisms. Since the cancer cells require high levels of glucose, the conditions of food poverty in the tumor environment can cause inactivation of immune cells, especially the T-effector cell...

journal_title：Current cancer drug targets

authors： Iranparast S,Tayebi S,Ahmadpour F,Yousefi B

更新日期：2020-01-01 00:00:00

abstract：:Wild-type Wilms' tumor gene WT1 is expressed at high levels not only in most of acute myelocytic, acute lymphocytic, and chronic myelocytic leukemia, but also in various types of solid tumors including lung cancer. We tested the ability of the gene product (WT1) to serve as a target antigen for tumor specific immunot...

journal_title：Current cancer drug targets

authors： Oka Y,Tsuboi A,Elisseeva OA,Udaka K,Sugiyama H

更新日期：2002-03-01 00:00:00

abstract：:There is an emerging paradigm shift in oncology that seeks to emphasize molecularly targeted approaches for cancer prevention and therapy. Chalcones (1,3-diphenyl-2-propen-1-ones), naturally-occurring compounds with widespread distribution in spices, tea, beer, fruits and vegetables, consist of open-chain flavonoids i...

journal_title：Current cancer drug targets

authors： Jandial DD,Blair CA,Zhang S,Krill LS,Zhang YB,Zi X

更新日期：2014-01-01 00:00:00